{
  "docId": "019de073-d546-7099-b69b-fc409bd054ba",
  "docSlug": "a8472da99eed55bdf1e59eb3c42372d9",
  "documentTitle": "Silo Pharma | Investor Presentation Deck | 24 slides",
  "authorId": "silo-pharma",
  "authorName": "Silo Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 24,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide outlines a specific asset (SPU-21) under a license agreement with UMB, detailing market size, technical mechanism, and research status.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-d546-7099-b69b-fc409bd054ba/11",
  "deckHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba",
  "deckJsonHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba.json",
  "deckAnchorHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.85,
        "y": 0.05
      },
      "kind": "image",
      "text": "SiloPharma",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "292087e4-c56c-42a5-922c-8d4a3151f2be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.64,
        "y": 0.23
      },
      "kind": "list",
      "text": "Applications\n- Identify markers of arthritic inflammation in joints\n- Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats\n- Peptide significantly inhibited arthritic progression in this animal model\n- Further studies underway at UMB",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "732c67b1-ae88-4191-9eb2-95511d7ad283",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.34,
        "y": 0.23
      },
      "kind": "list",
      "text": "Market Opportunity: Rheumatoid Arthritis (RA)\n- 1.3M U.S. adults suffer from RA\n- The most common autoimmune disease in U.S.\n- U.S. market for RA drugs expected to reach $63 billion by 2027",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad378d72-ca1a-4fe9-ac65-98ff01ed1a47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.34,
        "y": 0.62
      },
      "kind": "list",
      "text": "Technology\n- Development plan to utilize liposomal homing peptide to deliver targeted psilocybin\n- Ability to target inflamed epithelium suggests possibility to target drug delivery\n- Approach could enhance therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug\n- Potential to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis\n- Could be customizable and used to deliver nanoparticles for precise imaging\n- Could be used to treat autoimmune diseases other than RA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3e615da-3aca-4ed6-a3c0-78039b94bc98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "title",
      "text": "SPU-21 Joint Homing Peptides Targeting Rheumatoid Arthritis",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c94a9f18-ced2-48fe-8466-bcae95b9b343",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.105,
        "y": 0.08
      },
      "kind": "title",
      "text": "UMB CELA (Commercial Evaluation License Agreement)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c5ccf88-a217-4d69-a355-addc37bd1432",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "7eef8438-24a9-41be-8257-c3233f0d4ebf",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented in the Zylö Therapeutics Joint Venture and UMB License Agreement sections",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}